Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Clinical Case 2: High-Risk Early-Stage HR+ Breast Cancer

July 27th 2023

Rachel Layman, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Ongoing Second-Line Trials in Patients with HER2+ mBC and Expert Clinical Perspective

July 27th 2023

Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.

Selecting Endocrine Therapy in BRCA1/BRCA2+ Breast Cancer

July 27th 2023

Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.

Expanding Definitions of HER2 Expression Mediate the Role of ADCs in Breast Cancer

July 26th 2023

Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.

Dr O’Brien on Advances in Molecular Imaging in ER+ Breast Cancer

July 26th 2023

Sophia R. O'Brien, MD, discusses recent advances in the diagnosis and staging of estrogen receptor–positive metastatic breast cancer.

Advances in Early-Stage Breast Cancer Pull Biology and Biomarkers Into Focus

July 25th 2023

As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease.

The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings

July 25th 2023

Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.

Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials

July 25th 2023

Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.

Tinengotinib Elicits Clinical Benefit in Pretreated Cholangiocarcinoma and Other Advanced Solid Tumors

July 24th 2023

Sanjay Goel, MD, MS, expands on the findings from the phase 1b/2 trial, noting the potential benefit this approach may have for patients with cholangiocarcinoma, and detailed next steps for investigating tinengotinib.

Regional Nodal Irradiation Has Minimal Effect on Locoregional Recurrence in Favorable-Risk, Node-Positive Breast Cancer

July 23rd 2023

Locoregional recurrence rates among patients with favorable-risk, node-positive hormone receptor-positive, HER2-negative breast cancer was not significantly reduced by the addition of regional nodal irradiation to these patient’s treatment regimens.

ASCP’s Outstanding Education Initiatives Receive Prestigious Awards

July 21st 2023

Two innovative ASCP education initiatives have received accolades from the Alliance for Continuing Education in the Health Professions.

Dr Krop on Age-Related Survival Outcomes With T-DXd in HER2+ Breast Cancer

July 21st 2023

Ian E. Krop, MD, PhD, discusses the use of fam-trastuzumab deruxtecan-nxki across age groups in the DESTINY Breast trials in patients with HER2-positive metastatic breast cancer.

Use of ADCs in the Second-Line Treatment of HER2+ mBC

July 20th 2023

Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.

Implementing Trial Data to Our Practice

July 20th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

Standard-of-Care and Emerging Therapies for First-line Treatment of HER2+ mBC

July 20th 2023

Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.

Dosing CDK 4/6 Inhibitors

July 20th 2023

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

Unmet Needs and Clinical Pearls in the Treatment of HER2+ mBC

July 20th 2023

Megan Kruse, MD, offers advice to community oncologists treating HER2+ metastatic breast cancer and discusses unmet needs in the treatment landscape.

Breast Cancer Management: Future Directions in Fertility Preservation

July 19th 2023

Closing out their discussion on fertility preservation in breast cancer, Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, look toward unmet needs and future evolutions in the treatment landscape and offer advice for community physicians.

Timing Fertility Preservation in Patients With Breast Cancer Undergoing Surgery

July 19th 2023

Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, review fertility preservation strategies in the context of patients with breast cancer undergoing surgery.

CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting

July 18th 2023

The expert panel reviews CDK4/6 inhibitor options in the HR+/HER2- metastatic breast cancer (mBC) setting and previous data supporting their use.